

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

VISEN Pharmaceuticals
维昇药业
(incorporated in the Cayman Islands with limited liability)
(Stock code: 2561)

FINANCIAL RESULTS
FOR THE YEAR ENDED DECEMBER 31, 2024

This announcement is issued by VISEN Pharmaceuticals (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to the Note to Rule 13.49(1) of The Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

Shareholders and potential investors of the Company are reminded that the preliminary results of the Group for the year ended December 31, 2024 (as prescribed by Rule 13.49(1) of the Listing Rules) were included in “Unaudited Preliminary Financial Information for the Year Ended December 31, 2024” in Appendix IIB to the prospectus of the Company dated March 13, 2025, which is available for viewing on the website of the Stock Exchange (www.hkexnews.hk) and the website of the Company (www.visenpharma.com).

By order of the Board
VISEN Pharmaceuticals
Mr. LU An-Bang
Executive Director and Chief Executive Officer

Hong Kong, March 27, 2025

As at the date of this announcement, the board of directors of the Company comprises (i) Mr. LU An-bang as executive director; (ii) Mr. Michael Wolff JENSEN, Mr. Jan Møller MIKKELSEN, Mr. FU Shan, Mr. Michael J. CHANG and Mr. CAO Yibo as non-executive directors; and (iii) Dr. YAO Zhengbin (Bing), Mr. CHAN Peng Kuan and Ms. NI Hong as independent non-executive directors.